UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 42

Sortiert nach

Depression, Anxiety and Stress among Undergraduate Medical Students during the COVID-19 Pandemic

Healthline (Gujarat India), 2022-06, Vol.13 (2), p.178-182

2022

Volltextzugriff (PDF)

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

The Lancet (British edition), 2015-02, Vol.385 (9967), p.517-528

2015

Volltextzugriff (PDF)

Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL

Journal of clinical oncology, 2021-05, Vol.39 (15), p.1650-1659

2021

Volltextzugriff (PDF)

CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial

Journal of clinical oncology, 2020-06, Vol.38 (17), p.1938-1950

2020

Volltextzugriff (PDF)

Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL

Journal of clinical oncology, 2022-03, Vol.40 (9), p.932-944

2022

Volltextzugriff (PDF)

Donor source and post‐transplantation cyclophosphamide influence outcome in allogeneic stem cell transplantation for GATA2 deficiency

British journal of haematology, 2022-01, Vol.196 (1), p.169-178

2022

Volltextzugriff (PDF)

A Systematic Review of Pediatric Phase I Trials in Oncology: Toxicity and Outcomes in the Era of Targeted Therapies

The oncologist (Dayton, Ohio), 2020-06, Vol.25 (6), p.532-540

2020

Volltextzugriff (PDF)

Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days

Blood advances, 2021-12, Vol.5 (23), p.5312-5322

2021

Volltextzugriff (PDF)

Adverse Events Following CAR T-Cell Therapy: A Single Institution Retrospective Analysis of Toxicities Following CAR T-Cell Therapy for Children and Young Adults with Relapsed Refractory B-Cell Acute Lymphoblastic Leukemia

Blood, 2021-11, Vol.138 (Supplement 1), p.1731-1731

2021

Volltextzugriff (PDF)

The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes

Blood advances, 2022-12, Vol.6 (23), p.6040-6050

2022

Volltextzugriff (PDF)

"… the way we welcome them is how we will lead them to love family planning.": family planning providers in Rwanda foster compassionate relationships with clients despite workplace challenges

BMC health services research, 2021-04, Vol.21 (1), p.293-293, Article 293

2021

Volltextzugriff (PDF)

Factors Impacting Overall and Event-Free Survival following Post-Chimeric Antigen Receptor T Cell Consolidative Hematopoietic Stem Cell Transplantation

Transplantation and cellular therapy, 2022-01, Vol.28 (1), p.31.e1-31.e9

2022

Volltextzugriff (PDF)

Pediatric Cancer Immunotherapy and Potential for Impact on Fertility: A Need for Evidence-Based Guidance

Transplantation and cellular therapy, 2024-08, Vol.30 (8), p.737-749

2024

Volltextzugriff (PDF)

Procalcitonin and cytokine profiles in engraftment syndrome in pediatric stem cell transplantation

Pediatric blood & cancer, 2017-03, Vol.64 (3), p.np-n/a

2017

Volltextzugriff (PDF)

Hematopoietic Cell Transplantation for DOCK8 Deficiency: Results from a Prospective Clinical Trial

Journal of allergy and clinical immunology, 2024-09

2024

Volltextzugriff (PDF)

Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure

Transplantation and cellular therapy, 2023-09, Vol.29 (9), p.574.e1-574.e10

2023

Volltextzugriff (PDF)

Family planning providers and contraceptive users in Rwanda employ strategies to prevent discontinuation

BMC women's health, 2021-10, Vol.21 (1), p.361-361, Article 361

2021

Volltextzugriff (PDF)

Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy

Blood advances, 2022-09, Vol.6 (17), p.5222-5226

2022

Volltextzugriff (PDF)

Systematic review of pediatric oncology phase I trials: Toxicity and outcomes in the era of targeted therapies

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.2536-2536

2018

Volltextzugriff (PDF)

A comprehensive analysis of adverse events in the first 30 days of phase 1 pediatric CAR T-cell trials

Blood advances, 2023-09, Vol.7 (18), p.5566-5578

2023

Volltextzugriff (PDF)

1 – 25 von 42

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(42)

Publikationsform

Artikel
(42)

Sprache

Englisch
(42)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(20)
Life Sciences & Biomedicine
(19)
Humans
(18)
Hematology
(12)
Child
(9)
Adolescent
(8)
Adult
(8)
Female
(8)
Antigens, Cd19
(7)
Family Planning
(7)
Male
(7)
Young Adult
(7)
Birth Control
(6)
Child, Preschool
(6)
Focus Groups
(6)
Immunotherapy, Adoptive - Adverse Effects
(6)
Rwanda
(6)
Contraception
(5)
Contraceptives
(5)
Family Planning Services
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Depression, Anxiety and Stress among Undergraduate Medical Students during the COVID-19 Pandemic

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL

CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial

Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL

Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells

Donor source and post‐transplantation cyclophosphamide influence outcome in allogeneic stem cell transplantation for GATA2 deficiency

CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR

A Systematic Review of Pediatric Phase I Trials in Oncology: Toxicity and Outcomes in the Era of Targeted Therapies

Family planning demand generation in Rwanda: Government efforts at the national and community level impact interpersonal communication and family norms

Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells

Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days

Adverse Events Following CAR T-Cell Therapy: A Single Institution Retrospective Analysis of Toxicities Following CAR T-Cell Therapy for Children and Young Adults with Relapsed Refractory B-Cell Acute Lymphoblastic Leukemia

"…we have to think first what we are going to feed our children before we have them …": Rwandan women use family planning to provide a better life for their children

The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes

"… the way we welcome them is how we will lead them to love family planning.": family planning providers in Rwanda foster compassionate relationships with clients despite workplace challenges

Factors Impacting Overall and Event-Free Survival following Post-Chimeric Antigen Receptor T Cell Consolidative Hematopoietic Stem Cell Transplantation

Pediatric Cancer Immunotherapy and Potential for Impact on Fertility: A Need for Evidence-Based Guidance

Procalcitonin and cytokine profiles in engraftment syndrome in pediatric stem cell transplantation

Hematopoietic Cell Transplantation for DOCK8 Deficiency: Results from a Prospective Clinical Trial

Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure

Family planning providers and contraceptive users in Rwanda employ strategies to prevent discontinuation

Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy

Systematic review of pediatric oncology phase I trials: Toxicity and outcomes in the era of targeted therapies

A comprehensive analysis of adverse events in the first 30 days of phase 1 pediatric CAR T-cell trials

Suchergebnisse filtern